Antineoplaston AS2-1 for maintenance therapy in liver cancer
- H Tsuda
- M Sata
- H Saitsu
- K Yamana
- H Hara
- S Yamada
- T Kumabe
Affiliations: KURUME UNIV,SCH MED,DEPT SURG,KURUME,FUKUOKA 830,JAPAN. KURUME UNIV,SCH MED,DEPT INTERNAL MED,KURUME,FUKUOKA 830,JAPAN. KURUME UNIV,SCH MED,DEPT RADIOL,KURUME,FUKUOKA 830,JAPAN.
- Published online on: November 1, 1997 https://doi.org/10.3892/or.4.6.1213
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Antineoplaston AS2-1 exhibits cytostatic growth inhibition of human hepatocellular carcinoma cells in vitro and showed minimum adverse effects in a phase I clinical trial. Liver cancer is difficult to control because of multicentricity and underlying liver disease. We reviewed two clinical cases of liver cancer (hepatocellular carcinoma and multiple liver metastases from colon cancer) in whom we believe antineoplaston A2-1 was useful as a maintenance therapy after transcatheter arterial embolization (TAE) and microwave coagulation necrosis (MCN). The two patients have continued to be in good condition for more than two years without limitation of their normal activities. Antineoplaston AS2-1 may be effective and useful as a maintenance agent after TAE and MCN in patients with liver cancer.